Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75

Describe and Evaluate the Impact of Polypharmacy on Healthy Aging in People Living With HIV Over the Age of 75 Who Are Being Treated at Nice University Hospital.

Since the advent of antiretroviral treatments, the life expectancy of people living with HIV (PLHIV) has increased significantly. In France, more than 30% of PLHIV are now over 50 years old. This population is exposed to high multimorbidity, leading to frequent polypharmacy, defined as the regular use of at least five medications. Polypharmacy also has a qualitative dimension, including potentially inappropriate prescriptions. It increases the risk of adverse effects and drug interactions and impairs quality of life. A coordinated geriatric approach is therefore essential to optimize care. Healthy aging, promoted by the WHO, aims to improve the lives of older people. In this context, a study will be conducted at the Nice University Hospital among PLHIV aged 75 and over. It will collect quantitative data, the results of which will enable us to consider, if necessary, adapting the care pathways of these patients whose needs are complex.

Inclusion Criteria:

• HIV-positive
• Aged 75 or over
• Affiliated with the social security system
• Having expressed no objection to participating in the study

Exclusion Criteria:

• Refusal to participate
• Known severe cognitive impairment preventing the interview from being conducted
• Patient under guardianship or conservatorship